Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2022-12-26 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物第二届董事会第六次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of Hangzhou Anxu Biotechnology Co., Ltd. It details the resignation of the financial director and appointment of a new financial director, as well as the approval of an insider information management system. The document includes voting results and references to compliance with company law and stock exchange rules. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is clearly a Board/Management Information announcement regarding changes in senior management and governance policies.
2022-12-26 Chinese
安旭生物关于公司及相关人员收到浙江证监局警示函的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding a warning letter received from the Zhejiang Securities Regulatory Bureau. It details regulatory findings about accounting and governance issues, the regulatory measures taken, and the company's response and commitment to rectify the issues. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a regulatory announcement about legal and compliance matters involving the company and its executives. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2022-12-23 Chinese
安旭生物关于公司相关检测产品获得日本PMDA认证的自愿披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Hangzhou Anxu Biotech Co., Ltd. regarding the certification of a COVID-19 antigen test product by the Japanese PMDA (Pharmaceuticals and Medical Devices Agency). It provides details about the certification, the product, and the potential impact on the company. The document is short (920 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is an announcement about a regulatory certification related to product approval rather than a financial report or management information. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing in the sense of compliance or officer certification. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-11-30 Chinese
安旭生物关于公司相关检测产品获得美国FDA认证的自愿披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Hangzhou Anxu Biotechnology Co., Ltd. regarding the FDA emergency use authorization (EUA) certification of their COVID-19 Antigen Home Test product. It includes details about the certification, its impact on the company, and a risk warning to investors. The document is short (1121 characters) and serves as an official announcement of a regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about product certification and market impact.
2022-11-22 Chinese
安旭生物关于召开2022年第三季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2022 third quarter earnings explanation meeting (业绩说明会). It mentions the date, time, location, and participation method for the meeting, which is a form of investor presentation or earnings call. However, the document itself does not contain actual financial data or detailed financial results, only information about the upcoming event where such data will be discussed. The document length is short (1515 characters), and it serves as a notice for the event rather than the event transcript or report itself. Therefore, it fits best under the category of Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials and company performance, albeit in announcement form for the meeting. It is not a full earnings release (ER) or interim report (IR) because it lacks financial data. It is not a Report Publication Announcement (RPA) because it is not announcing the release of a report but the holding of a meeting. Hence, the classification is IP with high confidence.
2022-11-18 Chinese
安旭生物独立董事关于第二届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Hangzhou Anxu Biotechnology Co., Ltd. regarding matters discussed at the company's second board of directors' fifth meeting. It focuses on the use of surplus raised funds and changes in the implementation subject and location of fundraising investment projects. The document is a formal opinion related to board meeting decisions, not a full financial report or earnings release. It does not contain financial statements or detailed financial data. It is not a regulatory filing or announcement of voting results but rather a management/board-related opinion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management opinions.
2022-11-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.